» Articles » PMID: 19672139

Role of GABRA2 on Risk for Alcohol, Nicotine, and Cannabis Dependence in the Iowa Adoption Studies

Overview
Journal Psychiatr Genet
Specialty Neurology
Date 2009 Aug 13
PMID 19672139
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: A number of studies have shown that genetic variation at GABRA2 alters vulnerability to alcohol dependence. The exact identity of the causal variant(s), and the relationship of these variants to other forms of substance use and behavioral illness is, however, uncertain.

Objective: Therefore, we genotyped 516 individuals from the Iowa Adoption Studies, a large longitudinal case and control adoption study of substance use, at 39 single nucleotide polymorphisms encompassing the GABRA2 locus and analyzed them with respect to their lifetime history of three common forms of substance use dependence [alcohol dependence (AD), nicotine dependence (ND), and cannabis dependence (CD)] in the Iowa Adoption Studies and relevant exposure variables.

Result: Using regression analysis, we found substantial evidence that both GABRA2 genotype and haplotype are significantly related to vulnerability to AD, ND, and CD, with the strongest relationships noted with respect to ND. Consistent with earlier studies suggesting exposure is an important step in the development of substance use, we found the inclusion of substance exposure data in our analytic models markedly increased the strength of the genetic associations of GABRA2 haplotype with substance use. Finally, we report that the genetic effects were markedly more pronounced in females than in males.

Conclusion: We conclude that genetic variation at or near the GABRA2 locus significantly affects vulnerability not only to AD, but to other forms of substance use including ND and CD, and that the effects may be sex dependent.

Citing Articles

"Weeding out" violence? Translational perspectives on the neuropsychobiological links between cannabis and aggression.

Bortolato M, Braccagni G, Pederson C, Floris G, Fite P Aggress Violent Behav. 2024; 78.

PMID: 38828012 PMC: 11141739. DOI: 10.1016/j.avb.2024.101948.


The collaborative study on the genetics of alcoholism: Brain function.

Meyers J, Brislin S, Kamarajan C, Plawecki M, Chorlian D, Anohkin A Genes Brain Behav. 2023; 22(5):e12862.

PMID: 37587903 PMC: 10550791. DOI: 10.1111/gbb.12862.


The genetic aetiology of cannabis use: from twin models to genome-wide association studies and beyond.

Verweij K, Vink J, Abdellaoui A, Gillespie N, Derks E, Treur J Transl Psychiatry. 2022; 12(1):489.

PMID: 36411281 PMC: 9678872. DOI: 10.1038/s41398-022-02215-2.


Sleep deficits and cannabis use behaviors: an analysis of shared genetics using linkage disequilibrium score regression and polygenic risk prediction.

Winiger E, Ellingson J, Morrison C, Corley R, Pasman J, Wall T Sleep. 2020; 44(3).

PMID: 32935850 PMC: 7953210. DOI: 10.1093/sleep/zsaa188.


Genetics of Smoking Behaviors in American Indians.

Henderson J, Buchwald D, Howard B, Nez Henderson P, Li Y, Tyndale R Cancer Epidemiol Biomarkers Prev. 2020; 29(11):2180-2186.

PMID: 32855268 PMC: 8597394. DOI: 10.1158/1055-9965.EPI-20-0026.


References
1.
Philibert R, Madan A, Andersen A, Cadoret R, Packer H, Sandhu H . Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island. Am J Med Genet B Neuropsychiatr Genet. 2006; 144B(1):101-5. DOI: 10.1002/ajmg.b.30414. View

2.
Edenberg H, Dick D, Xuei X, Tian H, Almasy L, Bauer L . Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet. 2004; 74(4):705-14. PMC: 1181946. DOI: 10.1086/383283. View

3.
Stephens M, Smith N, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68(4):978-89. PMC: 1275651. DOI: 10.1086/319501. View

4.
Soyka M, Preuss U, Hesselbrock V, Zill P, Koller G, Bondy B . GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatr Res. 2007; 42(3):184-91. DOI: 10.1016/j.jpsychires.2006.11.006. View

5.
Philibert R, Gershenfeld H . Therapeutic potential of targeting gene variants in schizophrenia. Expert Rev Neurother. 2007; 7(7):757-60. DOI: 10.1586/14737175.7.7.757. View